Bristol-Myers Squibb Company (BMY) Status Update summary

Strategic priorities and portfolio focus

• Emphasis on science, execution, and value to drive innovation in hematology drug development.

• Portfolio discipline ensures resources are allocated to the most promising, differentiated assets.

• AI and machine learning are leveraged to accelerate R&D and improve clinical trial success rates.

• Decades of experience and a strong legacy in hematology underpin leadership in the field.

Pipeline highlights and clinical data

• CELMoDs iberdomide and mezigdomide show high efficacy and potential to replace current IMiDs in multiple myeloma.

• Iberdomide plus daratumumab and dexamethasone achieved a 95% overall response rate and over two-thirds MRD negativity in newly diagnosed, non-transplant patients.

• Mezigdomide combinations demonstrated over 80% response rates in early relapsed patients and manageable safety profiles.

• CELMoDs are being explored in novel combinations with T-cell engagers and as adjuncts to CAR-T therapy.

Cell therapy advancements

• Arlo-cel, a GPRC5D-targeting CAR-T, showed over 90% response rates and favorable safety in heavily pretreated multiple myeloma patients.

• Dual-targeting BCMA and GPRC5D CAR-T aims to prevent relapse and is in early clinical development.

• Breyanzi is now approved in five cancer types and is the leading CD19 CAR-T globally, with strong growth in both U.S. and international markets.